WebDoctor Encyclopedia

Childhood Genitourinary

Clear cell sarcoma of the kidney (CCSK)

Clear cell sarcoma of the kidney (CCSK) is an uncommon kidney cancer of young children, second in frequency only to Wilms tumour. It tends to spread to bone and is treated with nephrectomy, doxorubicin-based chemotherapy and radiotherapy.

Medically reviewed Last reviewed October 19, 2026

What is clear cell sarcoma of the kidney?

Clear cell sarcoma of the kidney (CCSK) is an uncommon kidney cancer of young children. Among malignant kidney tumours of childhood, only Wilms tumour is seen more often, yet CCSK still accounts for just 3-5% of all kidney tumours in children (Gooskens et al., 2012).

It usually affects young children, most often between the ages of 1 and 4 years, and it is more common in boys than in girls.

Despite its name, CCSK is not related to clear cell sarcoma of soft tissue, and it is not the same as clear cell renal cell carcinoma in adults. The name comes from the pale, “clear” appearance of the tumour cells under the microscope.

CCSK is more likely than Wilms tumour to spread to the bones, and in the past it was called the “bone-metastasising renal tumour of childhood”. It can also come back later, including in the brain.

Modern treatment with surgery, chemotherapy that includes doxorubicin, and radiotherapy cures most children (Furtwangler et al., 2013; Benedetti et al., 2024).

1. Key facts at a glance

Feature Details
Type of cancer Malignant kidney sarcoma of childhood
How common About 3-5% of childhood kidney tumours
Typical age Median about 2-3 years; rare in babies under 6 months and in adults
Sex About two-thirds are boys
Key symptoms Swollen abdomen or a lump, tummy pain, blood in the urine
Gene changes BCOR internal tandem duplication in most; YWHAE::NUTM2 fusion in some
Main treatment Removal of the kidney, chemotherapy with doxorubicin, radiotherapy
Outlook Good overall: about 86% survive at 5 years; excellent for stage I

2. Types and genetic groups

Group Notes
BCOR internal tandem duplication (BCOR-ITD) Found in about 80-90% of tumours (Roy et al., 2015)
YWHAE::NUTM2 fusion Found in about 10%
BCOR::CCNB3 fusion Rare
Histological patterns Classic, myxoid, sclerosing, cellular, epithelioid, palisading, spindle and others; the classic pattern is most common (Argani et al., 2000)

3. Causes and risk factors

The cause of CCSK is not known. The gene changes found in the tumour arise only in the tumour cells.

Question Answer
Is it inherited? No; CCSK is not linked with inherited syndromes
Is it linked with birth defects? No, unlike some Wilms tumours
Could anything have prevented it? No known cause or prevention
Is it infectious? No

Parents often wonder whether something during pregnancy or early childhood caused the tumour. There is no evidence that anything parents did, or did not do, played any role.

4. How does it look

On scans

Feature Description
Size Usually a large mass, often over 10 cm
Position Arising from one kidney, typically the central part
Appearance Solid with some cystic or dead areas; can look identical to Wilms tumour
Both kidneys Almost never affected together, unlike some Wilms tumours
Spread Lymph nodes, bones, lungs, liver and, at relapse, brain

Scans cannot reliably tell CCSK apart from Wilms tumour, so the diagnosis is made only after examination of tumour tissue.

To the surgeon

When the kidney is removed, the tumour is usually a large, soft, grey-tan mass with a mucoid, glistening surface and areas of cysts.

Under the microscope

Feature Description
Cells Nests or cords of cells with pale or clear cytoplasm
Blood vessels A fine, branching “chicken-wire” network of vessels between the cell nests
Patterns Many variants, which can make diagnosis difficult
Stains Strong nuclear BCOR and cyclin D1; negative for cytokeratin and WT1
Expert review Central pathology review is standard in childhood kidney tumour studies

Visible signs

Parents most often notice a swollen tummy or feel a firm lump in one side of the abdomen, for example during bathing. Some children look pale or have lost weight.

5. Symptoms

Common symptoms

  • A lump or swelling in the abdomen, often painless
  • Tummy pain
  • Blood in the urine, which may make it look pink, red or brown
  • Fever
  • Loss of appetite and weight loss
  • Tiredness or paleness from anaemia

Symptoms of spread

Site of spread Possible symptoms
Bone Bone pain, limping, refusing to walk or a fracture
Lungs Cough or breathlessness (often no symptoms)
Brain Headache, vomiting, seizures, weakness or changes in behaviour
Liver Swelling of the upper abdomen

Other possible signs

  • High blood pressure, causing headaches or irritability in some children
  • Constipation from pressure of the tumour on the bowel

When to seek medical advice

See a doctor promptly if your child has a lump or swelling in the tummy, blood in the urine, or ongoing tummy or bone pain.

Seek urgent help for severe headache with vomiting, a seizure, or severe tummy pain.

6. Diagnosis

Test Purpose
Ultrasound First scan; shows a kidney mass
CT or MRI of the abdomen Shows the size of the tumour, lymph nodes and blood vessels
CT of the chest Looks for lung spread
Bone scan or PET-CT Looks for bone spread, which is typical of CCSK
MRI of the brain Often done because of the risk of brain spread
Biopsy or nephrectomy Confirms the diagnosis
Molecular tests BCOR-ITD or YWHAE::NUTM2
Blood and urine tests Kidney function, blood count, blood pressure

Staging

CCSK uses the same staging system as Wilms tumour:

Stage Description
Stage I Confined to the kidney and completely removed
Stage II Spread beyond the kidney but completely removed
Stage III Tumour left in the abdomen, lymph node spread or tumour spill
Stage IV Spread to distant organs such as bones, lungs or brain

Conditions that can look similar

Condition How it differs
Wilms tumour The most common childhood kidney cancer; different cells and WT1-positive
Rhabdoid tumour of the kidney Very young babies; loss of INI1 (SMARCB1)
Congenital mesoblastic nephroma Babies under 6 months; ETV6::NTRK3 in the cellular type
Renal cell carcinoma Older children and teenagers
Neuroblastoma Arises from the adrenal gland; raised urine catecholamines

7. Treatment

Children with CCSK are treated at a specialist children’s cancer centre, usually within international protocols such as the SIOP-RTSG UMBRELLA protocol in Europe or Children’s Oncology Group (COG) studies in North America (Gooskens et al., 2018).

Surgery

The affected kidney is removed in an operation called a nephrectomy. Lymph nodes are sampled to help with staging.

Approach Description
European (SIOP) approach Several weeks of chemotherapy first (as for suspected Wilms tumour), then surgery
North American (COG) approach Surgery first, then chemotherapy

Both approaches give similar results for CCSK. Removing the kidney without breaking the tumour open is important, because tumour spill raises the stage and the amount of treatment needed.

Chemotherapy

Chemotherapy is given to all children after surgery and includes doxorubicin, which greatly improved outcomes (Argani et al., 2000; Seibel et al., 2019).

Typical drugs Notes
Vincristine, doxorubicin, cyclophosphamide Alternating with cyclophosphamide and etoposide, usually for about 6 months
Carboplatin Added for stage IV disease in some protocols
Treatment for relapse Ifosfamide, carboplatin, etoposide, irinotecan and sometimes high-dose chemotherapy with stem cell rescue

Radiotherapy

Situation Radiotherapy
Stage I with lymph nodes sampled Often omitted in COG studies (Benedetti et al., 2024)
Stage II and III Radiotherapy to the kidney area (flank) or abdomen
Stage IV Radiotherapy to the kidney area and to metastatic sites

What treatment involves day to day

Treatment usually lasts about six months after surgery. A central line or port is placed under the skin of the chest so that chemotherapy can be given and blood samples taken without repeated needles.

Part of treatment What families can expect
Chemotherapy cycles Short hospital stays or day visits every few weeks
Between cycles Low blood counts for a week or two; extra care to avoid infections
Radiotherapy Daily short sessions over a few weeks; young children may need a light anaesthetic to keep still
Heart checks An echocardiogram before and during doxorubicin
Blood tests Frequent, to check blood counts and kidney function

Why CCSK is treated differently from Wilms tumour

Because CCSK and Wilms tumour can look the same on scans, many children start treatment as if they had Wilms tumour. Once the kidney is examined and CCSK is confirmed, treatment is intensified. Doxorubicin is added, and imaging of the bones and brain is arranged, because CCSK spreads to these sites more often than Wilms tumour does.

Side effects

Treatment Possible side effects
Chemotherapy Infections, hair loss, sickness, low blood counts
Doxorubicin Possible heart damage; heart scans are done during and after treatment
Cyclophosphamide Effects on fertility and bladder
Radiotherapy Effects on growth of the spine and muscles, bowel and remaining kidney
Loss of one kidney The other kidney usually works normally; regular blood pressure and kidney checks

8. Outlook (prognosis)

The outlook for children with CCSK has improved greatly over the decades.

Group Approximate outlook
All children (SIOP studies) About 79% event-free and 86% overall survival at 5 years (Furtwangler et al., 2013)
Stage I Excellent, with survival close to 100%
Stage II and III Good; most children are cured
Stage IV Poorer, though some children are still cured
Very young children Somewhat poorer outcomes

In COG studies, the 4-year event-free survival was over 80%, and many children with stage I disease did well even without radiotherapy (Benedetti et al., 2024).

Relapse

About 15% of children relapse. Relapses can occur late, sometimes several years after treatment, and the brain is one of the most common sites. Relapsed CCSK is harder to treat, but some children are cured with further surgery, radiotherapy and intensive chemotherapy (Gooskens et al., 2014).

9. Follow-up and long-term effects

Follow-up Purpose
Scans of the abdomen, chest and sometimes brain Detect relapse early; follow-up lasts many years because of late relapse
Heart scans After doxorubicin
Kidney function and blood pressure Monitor the remaining kidney
Growth and puberty Especially after radiotherapy
Fertility After cyclophosphamide and abdominal radiotherapy

10. Living with CCSK

  • Ask for a named key worker or specialist nurse
  • Report fever immediately during chemotherapy
  • Report new headaches, vomiting or bone pain during follow-up
  • Protect the remaining kidney by staying hydrated and avoiding unnecessary anti-inflammatory painkillers
  • Ask about play specialists to help young children cope with tests and treatment
  • Seek family support, including for brothers and sisters
  • Keep a treatment summary, listing doses of doxorubicin and radiotherapy, to share with doctors in adult life

11. Frequently asked questions

Question Answer
Is CCSK the same as Wilms tumour? No. It is a different kidney cancer, although it can look similar on scans
Can my child live with one kidney? Yes. One healthy kidney is enough for a normal life
Is CCSK inherited? No
Why are brain scans needed? CCSK can spread or relapse in the brain
Can it come back years later? Yes, late relapses occur, so long follow-up is important
Will my child need radiotherapy? Usually, except in some stage I cases
Can my child go to nursery or school? Often yes between treatments, with advice on infection risks such as chickenpox and measles
Are there new treatments? Researchers are studying how BCOR changes drive CCSK, which may lead to targeted treatments in the future

12. Questions to ask your care team

  • What stage is my child’s tumour?
  • Will my child have chemotherapy before or after surgery?
  • Is radiotherapy needed, and to which area?
  • What side effects could doxorubicin and radiotherapy have later in life?
  • How long will follow-up last, and which scans are needed?
  • Are there clinical trials for my child?

Resources

  1. Argani, P. et al. (2000) ‘Clear cell sarcoma of the kidney: a review of 351 cases from the National Wilms Tumor Study Group Pathology Center’, American Journal of Surgical Pathology, 24(1), pp. 4-18.
  2. Benedetti, D.J. et al. (2024) ‘Treatment and outcomes of clear cell sarcoma of the kidney: a report from the Children’s Oncology Group studies AREN0321 and AREN03B2’, Cancer, 130(13), pp. 2361-2371.
  3. Furtwangler, R. et al. (2013) ‘Clear cell sarcomas of the kidney registered on International Society of Pediatric Oncology (SIOP) 93-01 and SIOP 2001 protocols: a report of the SIOP Renal Tumour Study Group’, European Journal of Cancer, 49(16), pp. 3497-3506.
  4. Gooskens, S.L. et al. (2012) ‘Clear cell sarcoma of the kidney: a review’, European Journal of Cancer, 48(14), pp. 2219-2226.
  5. Gooskens, S.L. et al. (2014) ‘Treatment and outcome of patients with relapsed clear cell sarcoma of the kidney: a combined SIOP and AIEOP study’, British Journal of Cancer, 111(2), pp. 227-233.
  6. Gooskens, S.L. et al. (2018) ‘Position paper: rationale for the treatment of children with CCSK in the UMBRELLA SIOP-RTSG 2016 protocol’, Nature Reviews Urology, 15(5), pp. 309-319.
  7. Roy, A. et al. (2015) ‘Recurrent internal tandem duplications of BCOR in clear cell sarcoma of the kidney’, Nature Communications, 6, 8891.
  8. Seibel, N.L. et al. (2019) ‘Impact of cyclophosphamide and etoposide on outcome of clear cell sarcoma of the kidney treated on the National Wilms Tumor Study-5 (NWTS-5)’, Pediatric Blood and Cancer, 66(1), e27450.
  9. National Cancer Institute (2026) Wilms Tumor and Other Childhood Kidney Tumors Treatment (PDQ) – Health Professional Version. Available at: https://www.cancer.gov/types/kidney/hp/wilms-treatment-pdq (Accessed: October 2026).

Prepared by the editorial team, October 2026.